Altimmune (ALT) announced the appointment of Christophe Arbet-Engels, MD, PhD as Chief Medical Officer, effective October 1, 2025. Dr. Arbet-Engels joins the Company with more than 30 years of experience spanning industry, academia and private practice, and will lead the ongoing clinical development of pemvidutide including the planned Phase 3 trial in metabolic dysfunction-associated steatohepatitis. He succeeds Scott Harris, M.D., who earlier this year informed the Company of his plans to retire from the position. Dr. Harris will remain with the Company as a Senior Strategic Advisor until February 2026. Dr. Arbet-Engels joins Altimmune from X4 Pharmaceuticals (XFOR), where he served as CMO since 2023.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ALT:
- Altimmune Holds Annual Stockholders Meeting on Governance
- ALT Lawsuit Alert! Class Action Lawsuit Against Altimmune
- Altimmune’s Pemvidutide Advances: Analyst Recommends Buy with Promising Trial Milestones and Dual Mechanism Benefits
- Altimmune appoints Richardson as Chief Commercial Officer
- Altimmune’s Earnings Call Highlights NASH Trial Success and Financial Strength